You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 159 No. 22, December 13, 1999 TABLE OF CONTENTS
  Archives
  •  Online Features
  Commentary
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (3)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Cardiovascular System
 •Drug Therapy
 •Drug Therapy, Other
 •Congestive Heart Failure/ Cardiomyopathy
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

The Economics of Therapeutic Advances

The Paradigm of Sympathetic Suppression in Chronic Heart Failure

Arch Intern Med. 1999;159:2634-2636.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

THE IMPACT of a newly introduced therapeutic approach is mostly determined by 2 facts: (1) it addresses a common condition that affects large numbers of people and defines their functional status and quality of life for long periods of time; (2) it is inexpensive and readily available not only to those who live in technologically advanced societies, but also to those who live in the developing countries, where most of the world's population resides. While death rates from other cardiovascular diseases are decreasing, the incidence of death rates from heart failure has been increasing in recent years. Several factors account for this trend, including, ironically, the successful management of inflammatory or ischemic heart disease, hypertension, and other conditions that lead to heart failure, as well as increasing life expectancy. Indeed, today, heart failure is estimated to affect about 5 million people in the United States, of whom more than 75% . . . [Full Text of this Article]



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Using Measures of Disease Progression to Determine Therapeutic Effect: A Sirens' Song
Granger and McMurray
J Am Coll Cardiol 2006;48:434-437.
ABSTRACT | FULL TEXT  

A Dose of Our Own Medicine: Alternative Medicine, Conventional Medicine, and the Standards of Science
Morreim
J Law Med Ethics 2003;31:222-235.
 





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1999 American Medical Association. All Rights Reserved.